6. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular
Disease. N Engl J Med. 2017;377(2):111–121.
7. Dorsheimer L, Assmus B, Rasper T, et al. Association of Mutations Contributing to Clonal Hematopoiesis
With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol. 2019;4(1):25–33.
8. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency
accelerates atherosclerosis development in mice. Science. 2017;355(6327):842–847.
9. Sano S, Oshima K, Wang Y, et al. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through
a Mechanism Involving the IL-1β/NLRP3 Inflammasome. J. Am. Coll. Cardiol. 2018;71(8):875–886.
10. Steensma DP. Does early diagnosis and treatment of myelodysplastic syndromes make a difference? Best
Practice & Research Clinical Haematology. 2019;32(4):101099.
11. Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: Partners in leukemogenesis and
comorbidity. Exp Hematol. 2020.
12. Taylor J, Lee SC. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Genes Chromosom. Cancer. 2019;58(12):889–902.
13. Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and
Leukemia Progression. Cell. 2017;170(6):1079–1095.e20.
14. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic
Disease. N Engl J Med. 2017;377(12):1119–1131.